Pair page
GW-0742 with Testosterone
Mechanism-tag overlap and published literature for GW-0742 and Testosterone, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ppar-agonist
androgenprimary-male-sex-hormone
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying GW-0742 and Testosterone have published these mechanism-level observations. Not a co-administration recommendation.
TRT + PPARδ agonism is the classical "cutting cycle" bodybuilding combination — androgenic anabolic signaling paired with oxidative-metabolism reprogramming for simultaneous lean-mass preservation and fat loss. Requires clinician oversight; compounds PPARδ safety concerns.
Quick facts
GW-0742
Testosterone
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2008 | GW-0742 | Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F. Activation of pe… PMID 18285555 | human trial, Phase 2 |
| 2005 | GW-0742 | Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L. The PPARδ agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis. 2005;181(1):29-37. PMID: 15939051. (GW-0742 atherosclerosis data.) PMID 15939051 | preclinical, in vivo |
| 2005 | GW-0742 | Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;65(4):832-841. PMID: 15721862. (GW-0742 cardiac-h… PMID 15721862 | preclinical, in vivo |
| 2003 | GW-0742 | Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) — synthesis… PMID 12699745 | mechanism / discovery |
| 2012 | GW-0742 | Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12(3):181-195. PMID: 22318237. (Comprehensive review of PPARs and cancer risk — the central safety-framing source for the class.) PMID 22318237 | review |
| 2026 | GW-0742 | WADA. 2026 World Anti-Doping Code Prohibited List. Section S4.5 — Metabolic Modulators. World Anti-Doping Agency. Effective January 1, 2026. | regulatory / registry |
| 2018 | GW-0742 | Palomer X, Barroso E, Pizarro-Delgado J, Peña L, Botteri G, Zarei M, Aguilar D, Montori-Grau M, Vázquez-Carrera M. PPARβ/δ: a key therapeutic target in metabolic disorders. Int J Mol Sci. 2018;19(3):913. PMID: 29558390. PMID 29558390 | research article |
| 2016 | GW-0742 | Tan NS, Vázquez-Carrera M, Montagner A, Sng MK, Guillou H, Wahli W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ. Prog Lipid Res. 2016;64:98-122. PMID: 27665713. PMID 27665713 | research article |
| 2010 | GW-0742 | Wagner KD, Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2010;125(3):423-435. PMID: 20026354. PMID 20026354 | research article |
| 2008 | GW-0742 | Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809. PMID 18674809 | research article |
| 2007 | GW-0742 | Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis. 2007;28(12):2641-26… PMID 17693662 | research article |
| 2006 | GW-0742 | Barish GD, Narkar VA, Evans RM. PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116(3):590-597. PMID: 16511591. PMID 16511591 | research article |
| 2007 | Testosterone | Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis. Mayo Clin Proc. 2007;82(1):29-39. PMID: 17285783. PMID 17285783 | systematic review |
| 2015 | Testosterone | Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-279. PMID: 26797061. PMC4721027. PMID 26797061 | human trial, Phase 2 |
| 2018 | Testosterone | Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364. PMID 29562364 | human study |
| 2013 | Testosterone | Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. PMID: 24024838. PMID 24024838 | human study |
| 2008 | Testosterone | Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. PMID: 18160461. PMID 18160461 | human study |
| 2001 | Testosterone | Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. PMID: 11158037. PMID 11158037 | human study |
| 2025 | Testosterone | WADA. 2025 Prohibited List. Section S1 — Anabolic Agents. World Anti-Doping Agency. | regulatory / registry |
| 2023 | Testosterone | Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Stu… PMID 37326322 | research article |
| 2018 | Testosterone | Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923. PMID 29601923 | research article |
| 2016 | Testosterone | Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521. PMID 26886521 | research article |
| 2016 | Testosterone | Morgentaler A, Zitzmann M, Traish AM, Fox AW, Jones TH, Maggi M, Arver S, Aversa A, Chan JC, Dobs AS, Hackett GI, Hellstrom WJ, Lim P, Lunenfeld B, Mskhalaya G, Schulman CC, Torres LO. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Con… PMID 27313122 | research article |
| 2016 | Testosterone | Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-843. PMID: 28078214. PMID 28078214 | research article |
Related pair pages
More research context
Frequently asked
Have GW-0742 and Testosterone been studied together?
Researchers have published mechanistic-level co-administration discussion of GW-0742 and Testosterone. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do GW-0742 and Testosterone share?
GW-0742 and Testosterone do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of GW-0742 and Testosterone?
GW-0742: Never entered clinical trials. Testosterone: Approved (multiple formulations). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on GW-0742 and Testosterone?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the GW-0742 profile and the Testosterone profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026